Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Antonio Solana-Altabella"'
Autor:
David Martínez-Cuadrón, Juan E. Megías-Vericat, Cristina Gil, Teresa Bernal, Mar Tormo, Pilar Martínez-Sánchez, Carlos Rodríguez-Medina, Josefina Serrano, Pilar Herrera, José A. Pérez Simón, María J. Sayas, Juan Bergua, Esperanza Lavilla-Rubira, Maria Luz Amigo, Celina Benavente, Jose L. López Lorenzo, Manuel M. Pérez-Encinas, María B. Vidriales, Mercedes Colorado, Beatriz de Rueda, Raimundo García-Boyero, Sandra Marini, Julio García-Suárez, María López-Pavía, Maria I. Gómez-Roncero, Víctor Noriega, Aurelio López, Jorge Labrador, Ana Cabello, Claudia Sossa, Lorenzo Algarra, Mariana Stevenazzi, Antonio Solana-Altabella, Blanca Boluda, Pau Montesinos
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without inco
Externí odkaz:
https://doaj.org/article/f978279b26d241eca282876eec8ca76b
Autor:
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Antonio Solana-Altabella, José Luis Poveda, Pau Montesinos
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 878 (2022)
Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability in SLC and ABC could produc
Externí odkaz:
https://doaj.org/article/a7e82da54ede41f0a78377355c0fb65b
Autor:
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Publikováno v:
Expert Review of Clinical Pharmacology. 16:133-148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c194547949642de69e61b3ceb1e841bb
https://doi.org/10.1080/17512433.2023.2174523
https://doi.org/10.1080/17512433.2023.2174523
Autor:
David Martínez-Cuadrón, Juan E. Megías-Vericat, Cristina Gil, Teresa Bernal, Mar Tormo, Pilar Martínez-Sánchez, Carlos Rodríguez-Medina, Josefina Serrano, Pilar Herrera, José A. Pérez Simón, María J. Sayas, Juan Bergua, Esperanza Lavilla-Rubira, Maria Luz Amigo, Celina Benavente, Jose L. López Lorenzo, Manuel M. Pérez-Encinas, María B. Vidriales, Mercedes Colorado, Beatriz De Rueda, Raimundo García-Boyero, Sandra Marini, Julio García-Suárez, María López-Pavía, Maria I. Gómez-Roncero, Víctor Noriega, Aurelio López, Jorge Labrador, Ana Cabello, Claudia Sossa, Lorenzo Algarra, Mariana Stevenazzi, Antonio Solana-Altabella, Blanca Boluda, Pau Montesinos
Publikováno v:
Haematologica.
Treatment options for patients with secondary and myeloid related changes acute myeloid leukemia (sAML and AML-MRC) aged 60-75 years old are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37a5407c2b18ec6246330ca8c70f3eff
https://doi.org/10.3324/haematol.2022.282506
https://doi.org/10.3324/haematol.2022.282506
Autor:
Mayte Gil-Candel, Antonio Solana-Altabella, Esther Vicente-Escrig, Aarón Puplá-Bartoll, Julia Bodega Azuara, Pablo Pérez-Huertas, Raul Ferrando Piqueres
Publikováno v:
European Journal of Hospital Pharmacy. 30:107-112
This study aimed to describe the actions taken to implement a telepharmacy programme with home medication dispensing and informed delivery in an outpatient pharmaceutical care unit of a tertiary hospital, where approximately 5000 patients are treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2483e18d42fdef52b264171619e8a5
https://doi.org/10.1136/ejhpharm-2021-003194
https://doi.org/10.1136/ejhpharm-2021-003194
Autor:
Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Publikováno v:
EXPERT OPINION ON EMERGING DRUGS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
INTRODUCTION: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77fdcfb29ebeb4d98bc819e1a832e0d
https://doi.org/10.1080/14728214.2021.2009800
https://doi.org/10.1080/14728214.2021.2009800
Autor:
Miguel A. Sanz, Antonio Solana-Altabella, José Luis Piñana, Pau Montesinos, Rebeca Rodríguez-Veiga, Ignacio Lorenzo, David Martínez-Cuadrón, Javier Marco, Manuel Guerreiro, Pilar Solves, Juan Eduardo Megías-Vericat, Inés Gómez, Juan Montoro Gómez, Jaime Sanz, Evelyn Acuña-Cruz, Isabel Cano, Blanca Boluda, Albert Blanco, Octavio Ballesta-López, Alvaro Díaz-González
Publikováno v:
Journal of Clinical Apheresis
Background This study assessed pharmacoeconomic costs associated with extracorporeal photopheresis (ECP) compared with other available second‐line therapies for chronic graft‐vs‐host disease (cGvHD) in a tertiary Spanish institution. Methods Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2220ad17824997a589aecd1715bff1f
http://europepmc.org/articles/PMC8453768
http://europepmc.org/articles/PMC8453768
Autor:
Miguel A. Sanz, Antonio Solana-Altabella, José Luis Piñana, Javier Marco-Ayala, Rebeca Rodríguez-Veiga, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, José Cervera, David Martínez-Cuadrón, Eva Barragán, Amparo Sempere, Claudia Sargas, Blanca Boluda, Rosalía de la Puerta, Jaime Sanz, Albert Blanco, Isabel Cano, Evelyn Acuña-Cruz, Alvaro Díaz-González, Pau Montesinos
Publikováno v:
European Journal of Haematology. 106:724-733
BACKGROUND Information regarding impact on healthcare systems of relapsed or refractory (R/R) FLT3 mutated (FLT3mut) acute myeloid leukemia (AML) is scarce. OBJECTIVE To assess the time and reimbursement associated with hospitalizations of patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c523ad15fe3882e99d05e67005a551b
https://doi.org/10.1111/ejh.13604
https://doi.org/10.1111/ejh.13604
Autor:
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, David Martínez-Cuadrón, Evelyn Acuña-Cruz, Laura Torres-Miñana, Rebeca Rodríguez-Veiga, Irene Navarro-Vicente, David Martínez-Campuzano, Raquel García-Ruiz, Pilar Lloret, Pedro Asensi, Ana Osa-Sáez, Jaume Aguero, María Rodríguez-Serrano, Francisco Buendía-Fuentes, Juan Eduardo Megías-Vericat, Beatriz Martín-Herreros, Eva Barragán, Claudia Sargas, Maribel Salas, Margaret Wooddell, Charles Dharmani, Miguel A. Sanz, Javier De la Rubia, Pau Montesinos
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2267
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::259d8250aa0ea19b5eed9c591d5dab5a
https://doi.org/10.3390/cancers15082267
https://doi.org/10.3390/cancers15082267
Autor:
David Martínez-Cuadrón, Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Pau Montesinos, Octavio Ballesta-López
Publikováno v:
Future Oncology. 17:215-227
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is dismal with salvage standard approaches, and mutations of FMS-like tyrosine kinase 3 ( FLT3) gene, occurring in around 30% of AML patients may confer even poore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3a8c5b5064042a4197090708c0cd8f
https://doi.org/10.2217/fon-2020-0700
https://doi.org/10.2217/fon-2020-0700